A case of nonarteritic ischemic optic neuropathy (NAION) in a male patient taking sildenafil.
A case of nonarteritic ischemic optic neuropathy (NAION) in a male patient taking sildenafil.
复制标题
一例服用西地那非的男性患者出现非动脉炎性缺血性视神经病变 (NAION)。
DOI：
--
复制
发表时间：
2002
影响因子：
0.8
通讯作者：
S.A.W. Shakir
中科院分区：
文献类型：
--
作者：
A. Boshier;N. Pambakian;S.A.W. Shakir
西地那非是一种磷酸二酯酶-5抑制剂，用于治疗男性勃起功能障碍。我们报告了一例NAION病例，该病例是在1999年4月至6月期间由英格兰的初级保健医生开出的8893名患者(来自处方事件监测研究)开出的西地那非处方。这位61岁的患者有独立于药物治疗的NAION危险因素。不可能确信西地那非和NAION之间存在因果关系，尽管不能排除这种可能性。流行病学数据表明，在8893名受试者中可能会出现一例NAION病例。因此，对于临床医生来说，考虑NAION的危险因素范围仍然很重要；同时，同样需要像最近推出的任何药物制剂一样，继续进行药物警戒过程。
Sildenafil is a phosphodiesterase-type-5 inhibitor indicated for the treatment of erectile dysfunction in men. We report a case of NAION identified from a cohort of 8,893 patients (from a Prescription-Event Monitoring study) prescribed sildenafil by their primary care physician in England between April and June 1999. This 61-year-old patient had risk factors for NAION independent of drug therapy. It was not possible to be confident about a causal association between sildenafil and NAION, though the possibility could not be ruled out. Epidemiological data suggest that one case of NAION might be expected in a cohort of 8,893 subjects. Thus it remains important for clinicians to consider the range of risk factors for NAION; while equally, the processes of pharmacovigilance need to continue as for any recently launched drug preparation.